Search - tctmd.com

Displaying 441 - 460 of 687

Sort: Relevancy | Date

News Daily News

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Michael O'Riordan

September 12, 2018

News Daily News

TAVR Learning Curve, Volume-Outcome Relationship Highlighted in International Registry

Todd Neale

September 11, 2018

MITRA-FR in the Hot Seat as Experts Debate Impact on Guidelines and Practice

Shelley Wood

September 10, 2018

News Conference News PCR London Valves 2018

Clips and Rings for Tricuspid Regurgitation: Early Data Speak to Progress and Challenges

Shelley Wood

September 10, 2018

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Daily News

Late Conduction Defects After TAVR: Finding ‘Sweet Spot’ for Early Discharge

Michael O'Riordan

August 08, 2018

News Daily News

‘We Have to Go to Them’: New Global Initiative for Treating Rheumatic Heart Disease

Michael O'Riordan

August 06, 2018

News Daily News

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Shelley Wood

July 23, 2018

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

News Conference News The Structural Heart Disease Summit 2018

Hybrid Surgical/Interventional LV Reconstruction Improves Ejection Fraction and Patient Symptoms

Michael O'Riordan

June 27, 2018

News Conference News The Structural Heart Disease Summit 2018

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

Michael O'Riordan

June 26, 2018

News Conference News The Structural Heart Disease Summit 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Raj Makkar

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Raj Makkar, Maria Alu, MS

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Raj Makkar, Lars Sondergaard

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Surgical Perspectives of TMVR: Focus on Patient Selection and Clinical Management Issues

Presenter: Martin B. Leon, Gregg W. Stone, Michael J. Mack

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

Advertisement

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

TAVR Learning Curve, Volume-Outcome Relationship Highlighted in International Registry

MITRA-FR in the Hot Seat as Experts Debate Impact on Guidelines and Practice

Clips and Rings for Tricuspid Regurgitation: Early Data Speak to Progress and Challenges

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Late Conduction Defects After TAVR: Finding ‘Sweet Spot’ for Early Discharge

‘We Have to Go to Them’: New Global Initiative for Treating Rheumatic Heart Disease

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Hybrid Surgical/Interventional LV Reconstruction Improves Ejection Fraction and Patient Symptoms

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Surgical Perspectives of TMVR: Focus on Patient Selection and Clinical Management Issues

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content